Emergent BioSolutions (EBS) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($264.9 million vs $259.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | VCRE |
|---|---|---|
| Share price | $5.05 | $9.41 |
| Market cap | $259.65M | $264.89M |
| 1-day change | -1.94% | -5.09% |
| YTD return | -59.14% | — |
| 1-year return | -49.70% | — |
| 5-year return | -88.58% | — |
| Forward P/E | 4.83 | — |
| EPS (TTM) | $-5.00 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $742.90M | — |
| Revenue growth (YoY) | -28.81% | — |
| Net income (latest FY) | $52.60M | — |
| Gross margin | 56.09% | — |
| Operating margin | 13.47% | — |
| Net margin | 7.08% | — |
| 52-week high | $14.06 | $17.80 |
| 52-week low | $4.36 | $7.88 |
| Distance from 52-week high | -64.08% | -47.16% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +98.02% | +158.90% |
| Average volume | 1.11M | 23.31K |
| Shares outstanding | 51.42M | 28.16M |
| Employees | 900 | 50 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees
EBS vs VCRE FAQ
Which is bigger, Emergent BioSolutions or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $264.89M compared with $259.65M for Emergent BioSolutions (EBS).
Are Emergent BioSolutions and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.